What vaccinations are needed prior to starting multiple sclerosis treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vaccination Recommendations Prior to Multiple Sclerosis Treatment

Patients with multiple sclerosis should receive all recommended vaccinations at least 4-6 weeks before starting immunosuppressive therapy, with particular attention to pneumococcal, influenza, hepatitis B, and varicella zoster vaccines. 1, 2

Core Vaccination Principles for MS Patients

  • All vaccinations should be administered according to immunization guidelines at least 4 weeks prior to initiation of MS treatment for live or live-attenuated vaccines and at least 2 weeks prior for non-live vaccines 2
  • Live-attenuated vaccines are contraindicated during immunosuppressive therapy and until B-cell repletion occurs 2, 3
  • Vaccination should be considered before starting immunosuppressive treatment whenever the patient's clinical situation allows 4

Essential Vaccines Before MS Treatment

  • Pneumococcal vaccination: Recommended due to increased risk of invasive pneumococcal disease in immunocompromised individuals 1
  • Varicella zoster virus (VZV) vaccination: Particularly important for patients who will undergo immunosuppressive therapy due to high risk of herpes zoster infection 1, 2
  • Hepatitis B vaccination: Screen for HBV before initiation of treatment; vaccinate if negative for surface antigen and antibodies 2, 5
  • Influenza vaccination: Recommended annually 1, 3
  • COVID-19 vaccination: Recommended following national guidelines 1, 6

Timing Based on Specific MS Treatments

  • For ocrelizumab therapy: Complete all vaccinations at least 4-6 weeks before starting treatment 1, 7
  • For immune-reconstitution therapies (alemtuzumab, cladribine): Delay vaccination until at least 6 months after the last course of treatment if already on therapy 1, 6
  • For high-dose or long-term corticosteroids: Delay vaccination until 4-6 weeks after treatment cessation 6, 1
  • For anti-CD20 therapies (rituximab, ocrelizumab): If already on therapy, vaccination should be delayed for at least 6 months after the last dose for optimal response 6, 1

Vaccine Types and Safety Considerations

  • Inactivated vaccines (influenza, hepatitis B, pneumococcal): Generally safe for MS patients but may have reduced efficacy during immunosuppressive therapy 1, 8
  • Live-attenuated vaccines (MMR, varicella, zoster): Contraindicated during immunosuppressive therapy; must be given at least 4 weeks before starting treatment 2, 3
  • If immunosuppressive treatment is already established, live attenuated vaccines are absolutely contraindicated 4, 8

Practical Implementation

  • The time needed for completing a pre-MS treatment vaccination protocol can be as short as 27 days (median) 9
  • For vaccines with a correlate of protection, monitor the serological response 1-2 months after the last dose 4
  • Hepatitis B vaccination should be prioritized early in the diagnosis process, as protective antibody formation is significantly better when vaccination occurs before treatment (193 mIU/ml) compared to after treatment (0 mIU/ml) 5

Important Caveats

  • Disease-modifying therapies (DMTs) may reduce antibody response to vaccines, but vaccination is still strongly recommended 1, 8
  • If a patient is experiencing an MS relapse, vaccination should be delayed until the relapse resolves 3
  • For patients with active underlying disease, immunosuppressive therapy should be prioritized over vaccination if treatment cannot be delayed 6, 1
  • Clinicians must screen for latent infections before starting immunosuppressive therapy according to prescribing information 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.